This was not how Reshma Kewalramani imagined spending her first day as Vertex CEO. The 47-year-old nephrologist ought to’ve been in a spacious window workplace on the 14th flooring of the biotech’s glassy Boston Seaport headquarters, three rooms down from the place she had spent the final three years. There ought to have been household pictures on the desk, scientists buzzing within the labs beneath, and, ft away, executives she knew and trusted, briefing her on potential cures for sickle cell illness and diabetes.
As a substitute, on that bone-chillingly chilly day final spring, she was at a makeshift desk within the dimly lit basement of her residence outdoors Boston, a bivouac chosen as a result of it was closest to the Wifi router. Her closest companion was Ferris Bueller’s smug face on the wall and she or he spent the day leaping from Zoom name to Zoom name, apprehensive much less about making new medication than ensuring her workers have been protected and that the worldwide provide chain didn’t go away a cystic fibrosis affected person with out entry to the Vertex capsules that had modified their life. It was April 1, 2020.
“These are usually not what I assumed could be the 2 of the best priorities,” she tells me. “The protection of our individuals? You’re taking it without any consideration.”
The pandemic hit Vertex on the worst doable time. Over the past decade, CEO Jeffrey Leiden, a jovial however shrewd and commanding determine, had pushed the event of these CF medication, turning the commonest deadly genetic illness in US and Europe into, for 90% of sufferers, a treatable situation. Within the course of, they’d gone from a $6 billion to a $60 billion firm and gained the uncommon collective awe of the enterprise, medical and affected person communities. “I scream it from the rooftops,” says Bob Coughlin, former CEO of trade group MassBio, whose 19-year-old son has CF. “He’s an entire new particular person, I’m crammed with extra gratitude than I’ve ever had in my complete rattling life.”
Now, simply as Leiden handed the torch, your complete world was collapsing. It was a trial by wildfire for Kewalramani, who had already been an unlikely selection as CEO. The heads of huge biotechs are virtually solely businesspeople, executives whose chief job is to promote the medication the corporate has already developed and discover different corporations to accumulate. If they’ve MDs, additionally they have an MBA or 20 years of expertise in gross sales. All, traditionally, have been males.
Kewalramani was a clear-eyed, affable doctor who had educated at Boston’s most prestigious hospitals and spent 12 years operating trials at Amgen, however she had little expertise on the enterprise aspect of biotech. For the prior three years, main Vertex’s medical staff, she stood reverse the chief committee at key moments, explaining outcomes from trials she designed and ran in sickle cell and cystic fibrosis.
“She got here from the medical aspect, which was distinctive,” says Terry McGuire, founder and normal companion of the Boston-based biotech VC Polaris Companions. “It speaks to their want to actually deal with what’s happening within the clinic and for sufferers.” Certainly, Vertex had solely thought of physician-scientists for the position. That they had large plans for the position — for what they known as Vertex 3.0. Though they’d change into often called the CF firm, for years, Leiden advised anybody who would pay attention that he didn’t simply need to remodel one illness: He deliberate to make use of the lavish proceeds from these capsules to treatment CF utterly and both treatment or defang an Infernal Council of well-known illnesses: Sickle cell illness, diabetes, muscular dystrophy and ache, amongst others.
It was as formidable a plan as a biotech had ever put ahead, spanning medical disciplines from hematology to nephrology and applied sciences from old style capsules to new types of CRISPR gene modifying, they usually wanted somebody with unimpeachable scientific chops to hold it out. If Kewalramani and her staff can, they may change the face of drugs: Not only for one uncommon illness however a number of, and some not so uncommon ones as nicely. They may additionally set off the identical string of rancorous world debates which have adopted Vertex’s CF medication, as the corporate charged greater than what many nations stated they might pay. Kewalramani, whereas putting a much less abrasive tone than her predecessor, has pledged to maintain the identical pricing technique shifting ahead.
“We’re going to do what we did in CF,” Kewalramani tells me, echoing a promise she makes repeatedly. “Once more and time and again.” However first they must cope with Covid-19.
Premium subscription required
Unlock this text together with different advantages by subscribing to certainly one of our paid plans.